These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9184402)

  • 61. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.
    Chow FS; Benincosa LJ; Sheth SB; Wilson D; Davis CB; Minthorn EA; Jusko WJ
    Clin Pharmacol Ther; 2002 Apr; 71(4):235-45. PubMed ID: 11956506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
    Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
    Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
    Circulation; 1994 Oct; 90(4):1631-7. PubMed ID: 7923645
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
    Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
    Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
    Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
    Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML
    Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.
    Cushing DJ; Cooper WD; Cohen ML; McVoy JR; Sobel M; Harris RB
    Eur J Pharmacol; 2010 Jun; 635(1-3):165-70. PubMed ID: 20307530
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers.
    Sié P; Albarede JL; Robert M; Bouloux C; Lansen J; Chigot C; Correll S; Thouvenot JP; Boneu B
    Thromb Haemost; 1986 Feb; 55(1):86-9. PubMed ID: 2422778
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C; Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays.
    Nurmohamed MT; Berckmans RJ; Morriën-Salomons WM; Berends F; Hommes DW; Rijnierse JJ; Sturk A
    Thromb Haemost; 1994 Nov; 72(5):685-92. PubMed ID: 7900075
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
    Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
    Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical monitoring of hirudin and direct thrombin inhibitors.
    Nowak G
    Semin Thromb Hemost; 2001 Oct; 27(5):537-41. PubMed ID: 11668425
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B; Hund S; Madlener K; Unkrig C; Müller-Berghaus G
    Thromb Res; 1997 Jun; 86(5):373-83. PubMed ID: 9211628
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study.
    Parent F; Bridey F; Dreyfus M; Musset D; Grimon G; Duroux P; Meyer D; Simonneau G
    Thromb Haemost; 1993 Sep; 70(3):386-8. PubMed ID: 8259534
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction.
    Zeymer U; Mateblowski M; Neuhaus KL
    Eur Heart J; 1996 Dec; 17(12):1836-40. PubMed ID: 8960425
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
    Dormans TP; van Meyel JJ; Gerlag PG; Tan Y; Russel FG; Smits P
    J Am Coll Cardiol; 1996 Aug; 28(2):376-82. PubMed ID: 8800113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.